Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $111,188.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $50.54, for a total transaction of $111,188.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Tuesday, December 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The stock was sold at an average price of $59.46, for a total value of $130,812.00.
• On Monday, November 11th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $59.88, for a total value of $131,736.00.

Corcept Therapeutics Trading Up 1.2 %

Shares of Corcept Therapeutics stock traded up $0.60 during mid-day trading on Tuesday, hitting $51.66. The stock had a trading volume of 1,085,633 shares, compared to its average volume of 771,028. The firm has a 50-day moving average of $54.91 and a two-hundred day moving average of $44.33. The firm has a market cap of $5.41 billion, a P/E ratio of 41.00 and a beta of 0.56. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $62.22.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm had revenue of $182.55 million for the quarter, compared to analyst estimates of $171.97 million. During the same period in the previous year, the firm earned $0.28 EPS. Corcept Therapeutics’s revenue was up 47.7% on a year-over-year basis. Sell-side analysts forecast that Corcept Therapeutics Incorporated will post 1.35 earnings per share for the current year.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital Performance Advisors LLP purchased a new position in Corcept Therapeutics in the third quarter valued at $25,000. Kathleen S. Wright Associates Inc. acquired a new stake in Corcept Therapeutics during the third quarter worth approximately $36,000. USA Financial Formulas purchased a new stake in shares of Corcept Therapeutics during the 4th quarter worth approximately $54,000. GAMMA Investing LLC boosted its stake in Corcept Therapeutics by 85.4% in the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,147 shares in the last quarter. Finally, KBC Group NV grew its holdings in shares of Corcept Therapeutics by 21.3% during the third quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 496 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on CORT. Piper Sandler increased their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Finally, Truist Financial upped their price target on Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research report on Monday, September 30th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $65.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.